Abstract:Aim Antimicrobial resistance (AMR) has become a global concern. Developing novel antimicrobials is one of the most effective approaches in tackling AMR. Considering its relatively low cost and risk, drug repurposing has been proposed as a valuable approach for novel antimicrobial discovery. The aim of this study was to screen for antimicrobial compounds against Streptococcus suis, an important zoonotic bacterial pathogen, from an Food and Drug Administration (FDA)-approved drug library. Methods and Results In this study, we tested the antimicrobial activity of 1815 FDA-approved drugs against S. suis. Sixty-seven hits were obtained that showed a growth inhibition of more than 98%. After excluding already known antibiotics and antiseptics, 12 compounds were subjected to minimal inhibition concentration (MIC) assessment against S. suis. This showed that pralatrexate, daunorubicin (hydrochloride), teniposide, aclacinomycin A hydrochloride and floxuridine gave a relatively low MIC, ranging from 0.85 to 5.25 mu g/ml. Apart from pralatrexate, the remaining four drugs could also inhibit the growth of antimicrobial-resistant S. suis. It was also demonstrated that these four drugs had better efficacy against Gram-positive bacteria than Gram-negative bacteria. Cytotoxicity assays showed that floxuridine and teniposide had a relatively high 50% cytotoxic concentration (CC50). The in vivo efficacy of floxuridine was analysed using a Galleria mellonella larvae infection model, and the results showed that floxuridine was effective in treating S. suis infection in vivo. Conclusions Five compounds from the FDA-approved drug library showed high antimicrobial activity against S. suis, among which floxuridine displayed potent in vivo efficacy that is worth further development. Significance and Impact of Study Our study identified several antimicrobial compounds that are effective against S. suis, which provides a valuable starting point for further antimicrobial development.

Identifying Cell-Penetrating Peptides for Effectively Delivering Antimicrobial Molecules into Streptococcus suis

Cell-Penetrating Peptides in Infection and Immunization

Unlocking the Secrets of Streptococcus suis: A peptidomics comparison of virulent and non-virulent serotypes 2, 14, 18, and 19

Identification of efficient prokaryotic cell-penetrating peptides with applications in bacterial biotechnology

Overcoming Planktonic and Intracellular Staphylococcus Aureus-Associated Infection with a Cell-Penetrating Peptide-Conjugated Antimicrobial Peptide

Cell-Penetrating Antimicrobial Peptides with Anti-Infective Activity against Intracellular Pathogens

A High-Throughput Screening Approach for Bacterial Quorum Sensing Inhibitors (qsis) Against Aeromonas Hydrophila Infection

A Novel Lysin Ply1228 Provides Efficient Protection Against Streptococcus Suis Type 2 Infection in a Murine Bacteremia Model.

Combination of Cell-Penetrating Peptides with Nanoparticles for Therapeutic Application: A Review

Identifying Antisense Oligonucleotides to Disrupt Small RNA Regulated Antibiotic Resistance via a Cell-Free Transcription-Translation Platform

Conjugation of Cell-Penetrating Peptides to Antimicrobial Peptides Enhances Antibacterial Activity

Targeted and Intracellular Antibacterial Activity against S. agalactiae of the Chimeric Peptides Based on Pheromone and Cell-Penetrating Peptides

Antimicrobial compounds from an FDA-approved drug library with activity against Streptococcus suis

Pre-Absorbed Immunoproteomics: A Novel Method for the Detection of Streptococcus Suis Surface Proteins

The Population Structure, Antimicrobial Resistance, and Pathogenicity of Streptococcus Suis Cps31

Cell-Penetrating Peptide–Peptide Nucleic Acid Conjugates as a Tool for Protein Functional Elucidation in the Native Bacterium

[Development of Cell-Penetrating Peptides As Vectors for Drug Delivery].

Combined antimicrobial effect of two peptide nucleic acids against Staphylococcus aureus and S. pseudintermedius veterinary isolates

The role of cell‐penetrating peptides in potential anti‐cancer therapy

Evaluation of the Protective Efficacy of Four Novel Identified Membrane Associated Proteins of Streptococcus Suis Serotype 2.